Can a ‘super pill’ help shrink Big Pharma’s climate footprint?

A breakthrough in oral drug delivery technology is helping the pharmaceutical industry to cut plastic waste.

Introduction

The pharmaceutical industry, often criticized for its environmental impact, has made a significant stride towards sustainability by adopting innovative oral drug delivery technologies. One such breakthrough, the 'super pill' or Unigel™, has revolutionized the way medicines are packaged and delivered, contributing significantly to reducing plastic waste.

The Problem

Big Pharma, despite its significant contributions to healthcare, has faced criticism for its environmental footprint. The industry's reliance on single-use packaging materials has led to significant plastic waste, contributing to the growing global issue of plastic pollution. The pharmaceutical industry's carbon emissions also pose a substantial threat to the environment, as they are one of the largest contributors to greenhouse gas emissions.

The Solution

Unigel™ Technology

Unigel™ is a game-changing oral drug delivery technology developed by Sofgen Pharmaceuticals. It allows multiple chemically incompatible ingredients to coexist in a single softgel capsule, offering multiple benefits to patients and the environment alike. The technology supports various therapies, including the prevention of cardiovascular events and treatment for diabetes and other chronic diseases, while also providing environmental benefits by streamlining dosage and reducing the need for additional packaging materials.

Environmental Benefits

The technology reduces the demand for other packaging materials like cardboard, paper, and aluminum foil, thereby minimizing waste and the subsequent environmental impact. In a study commissioned by Sofgen Pharmaceuticals, the use of Unigel™ softgel products was found to have reduced the production and disposal of over 27.5 million blister packs in 2022 alone. This significant reduction in packaging waste translates directly to a substantial decrease in greenhouse gas emissions.

Broader Impact

Unigel™ also optimizes storage and distribution, resulting in reduced fuel and energy consumption. This broadens the environmental benefits across the supply chain, contributing to a healthier planet. The technology's ability to simplify treatments and reduce packaging waste has made it a crucial component in Big Pharma's journey towards achieving net-zero emissions.

Industry Response

The pharmaceutical industry has recognized the urgent need for sustainability and environmental stewardship. Market intelligence firm GlobalData conducted a series of polls to gauge the sector's priorities in improving sustainability. The results revealed that more than half of the respondents felt that Big Pharma was not doing enough to address environmental concerns. Despite this, a significant portion of the industry has committed to net-zero targets ahead of 2050 and is actively working to reduce their carbon footprint.

Future Outlook

As the industry continues to innovate, it is likely that regulation will become even more stringent, pushing pharmaceutical companies to prioritize sustainability. The future of Big Pharma may well be shaped by technologies like Unigel™, which not only improve patient care but also reduce environmental impact. With the industry's commitment to sustainability and innovation, it is possible to envision a future where pharmaceuticals are not only a lifeline but also a catalyst for a healthier planet.

Conclusion

The introduction of Unigel™ marks a significant step towards a more sustainable pharmaceutical industry. By reducing plastic waste and optimizing packaging, the technology is helping Big Pharma to shrink its climate footprint. As the industry continues to innovate and prioritize environmental stewardship, it is possible to envision a future where healthcare and sustainability go hand in hand.

Read more about the impact of Unigel™ on Big Pharma's climate footprint

Learn about the challenges and priorities in Big Pharma's journey to net zero

Understand how the drug industry's carbon impact could be cut by half